Malign Plevral Mezotelyoma Yönetimi

Abstract

Malign Plevral Mezotelyoma Yönetimi

Abstract

Malignant mesothelioma (MM) arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. MM is a rare and insidious neoplasm with a poor prognosis. Malignant pleural mesothelioma (MPM) is the most common type and typically arises from the mesothelial surfaces of the pleural cavity. MPM can be difficult to treat because most patients have advanced disease at presentation. The median survival of patients is between 6 and 18 months. However, carefully selected patients with localized disease who receive aggressive multimodality therapy have relatively prolonged survival. In this review, we aimed to evaluate the results of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy studies to improve survival in MPM.

Keywords

• Malignant Pleural Mesothelioma
• Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy

References

1. 1. Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17:525-534.
2. 2. Metintas M, Ozdemir N, Hillerdal G, et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med. 1999;93:349-355.
3. 3. Selma Metintas, Guntulu Ak, Muzaffer Metintas. Trends in malignant pleural mesothelioma in Eskisehir province of Turkey from January 1990 to December 2016. European Respiratory Journal 2017;50: PA1591.
4. 4. Pathology and Genetics: Tumors of the Lung, Pleura, Thymus, and Heart, IARC, 2004.
5. 5. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997;145:211-218.
6. 6. Gibb H, Fulcher K, Nagarajan S et al. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health. 2013;103:710-716.
7. 7. Bocchetta M, Eliasz S, De Marco MA et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008;68:1022-1029.
8. 8. Panou V, Gadiraju M, Wolin A et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018;36:2863-2871.

9. 9. Frank E. Mott. Mesothelioma: A Review. Ochsner J. 2012;12:70–79.
10. 10. Powers A, Carbone M. The role of environmental carcinogens, viruses, and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther 2002;1:348–353.
11. 11. Boutin C, Dumortier P, Rey F, et al. Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med 1996;153:444–449.
12. 12. Metintaş S, Batırel HF, Bayram H et al. Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program. Int J Environ Res Public Health. 2017;14.
13. 13. Metintas M, Hillerdal G, Metintas S, Dumortier P. Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch Environ Occup Health. 2010;65:86-93.
14. 14. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192-197.
15. 15. Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564-1573.
16. 16. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928-2935.
17. 17. Bayram M, Özkan D, Hayat E et al. Asbestos-Related Diseases in Turkey: Not Only Caused by Naturally Occurring Fibers, but Also by Industrial Exposures. Am J Respir Crit Care Med. 2018;199:656-659.
18. 18. Bayram M, Özkan D, Hayat E et al. Asbestos-Related Diseases in Turkey: Not Only Caused by Naturally Occurring Fibers, but Also by Industrial Exposures. Am J Respir Crit Care Med. 2018;199:656-659.
19. 19. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Annals of Oncol. 2007; 18: 1196–1202
20. 20. Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy andRadiation for Malignant Pleural Mesothelioma. J Clin Oncol. 2009;27:3007- 3013.
21. 21. Lang-Lazdunski L, Bille A, Belcher E et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6:1746-1752.
22. 22. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
23. 23. Santoro A, O’Brien ME, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3:756-763.
24. 24. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889.
25. 25. Utkan G, Büyükçelik A, Yalçın B et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung cancer. 2006;53:367- 374.
26. 26. Shukuya T, Takahaski T, Imai H et al. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respir Investig. 2014 ;52:101-106.
27. 27. Van den Bogaert DP, Pouw EM, Van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2006;1:25-30.
28. 28. Zalcman G, Mazieres J, Margery J et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405-1414.
29. 29. Krug LM, Kindler HL, Calvert H et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015;16:447-456.
30. 30. Kumar T, Patel N, Talwar A. Spontaneous regression of thoracic malignancies. Respir Med 2010; 104:1543–1545.
31. 31. Yamada N1, Oizumi S, Kikuchi E, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1543–1549.
32. 32. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540- 1550.
33. 33. Mok TSK, Wu YL, Kudaba I, et al; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet.2019;393:1819-1830.
34. 34. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
35. 35. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-1290.
36. 36. Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261-1273.
37. 37. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised. open-label, phase 1b trial. Lancet Oncol 2017;18:623–630.
38. 38. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT- 1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239-253.
39. 39. Disselhorst MJ, Quispel-Janssen J, Lalezari F et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7:260-270.
40. 40. Scherpereel A, Wallyn F, Albenda SM, Muck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol 2018;19:e161-172.